Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

被引：1

作者：

Singh, Aditi ^{[1
]}

Sridhar, Arthi ^{[1
]}

Poddar, Aastha ^{[2
]}

Dimou, Anastasios ^{[1
]}

Parikh, Kaushal ^{[1
]}

Shanshal, Mohamed ^{[1
]}

Schwecke, Anna ^{[1
]}

Moffett, Nicole ^{[1
]}

Patel, Manish R. ^{[3
]}

Mansfield, Aaron S. ^{[1
]}

Leventakos, Konstantinos ^{[1
]}

机构：

[1] Mayo Clin, Dept Med Oncol, Rochester, MN USA

[2] Mayo Clin, Dept Hlth Sci Res, Coll Med, Rochester, MN USA

[3] Univ Minnesota, Med Sch, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

来源：

JTO CLINICAL AND RESEARCH REPORTS | 2025年 / 6卷 / 06期

关键词：

NSCLC; SCLC; EGFR; Osimertinib; Lurbinectedin; Tranformed SCLC; Drug resistance; CELL LUNG-CANCER; OPEN-LABEL;

D O I：

10.1016/j.jtocrr.2025.100807

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC, it is important to study treatment options that are safe and effective this disease. In this case series, three patients received treatment with lurbinectedin plus osimertinib after transformation to SCLC. In our limited experience, the combination was found to be safe. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页数：6

共 13 条

[1] Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial [J].

Aix, Santiago Ponce ;

Ciuleanu, Tudor Eliade ;

Navarro, Alejandro ;

Cousin, Sophie ;

Bonanno, Laura ;

Smit, Egbert F. ;

Chiappori, Alberto ;

Olmedo, Maria Eugenia ;

Horvath, Ildiko ;

Grohe, Christian ;

Farago, Anna F. ;

Lopez-Vilarino, Jose Antonio ;

Cullell-Young, Martin ;

Nieto, Antonio ;

Vasco, Noelia ;

Gomez, Javier ;

Kahatt, Carmen ;

Zeaiter, Ali ;

Carcereny, Enric ;

Roubec, Jaromir ;

Syrigos, Konstantinos ;

Lo, Gregory ;

Barneto, Isidoro ;

Pope, Anthony ;

Sanchez, Amparo ;

Kattan, Joseph ;

Zarogoulidis, Konstantinos ;

Waller, Cornelius F. ;

Bischoff, Helge ;

Juan-Vidal, Oscar ;

Reinmuth, Niels ;

Domine, Manuel ;

Paz-Ares, Luis .

LANCET RESPIRATORY MEDICINE, 2023, 11 (01) :74-86

[2] De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways [J].

Chakraborty, Subhamoy ;

Coleman, Charles ;

Manoj, Parvathy ;

Demircioglu, Deniz ;

Shah, Nisargbhai ;

de Stanchina, Elisa ;

Rudin, Charles M. ;

Hasson, Dan ;

Sen, Triparna .

CLINICAL CANCER RESEARCH, 2023, 29 (17) :3526-3540

[3] Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer [J].

Desai, Aakash ;

Smith, Caleb J. ;

Ashara, Yash ;

Orme, Jacob J. ;

Zanwar, Saurabh ;

Potter, Ashley ;

Hocum, Craig ;

Moffett, J. Nicole ;

Schwecke, Anna J. ;

Manochakian, Rami ;

Lou, Yanyan ;

Zhao, Yujie ;

Ernani, Vinicius ;

Savvides, Panos ;

Molina, Julian ;

Dimou, Anastasios ;

Mansfield, Aaron S. ;

Parikh, Kaushal ;

Leventakos, Konstantinos .

CLINICAL LUNG CANCER, 2023, 24 (08) :689-+

[4] Advances for studying clonal evolution in cancer [J].

Ding, Li ;

Raphael, Benjamin J. ;

Chen, Feng ;

Wendl, Michael C. .

CANCER LETTERS, 2013, 340 (02) :212-219

[5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer [J].

Leonetti, Alessandro ;

Sharma, Sugandhi ;

Minari, Roberta ;

Perego, Paola ;

Giovannetti, Elisa ;

Tiseo, Marcello .

BRITISH JOURNAL OF CANCER, 2019, 121 (09) :725-737

[6] EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes [J].

Marcoux, Nicolas ;

Gettinger, Scott N. ;

O'Kane, Grainne ;

Arbour, Kathryn C. ;

Neal, Joel W. ;

Husain, Hatim ;

Evans, Tracey L. ;

Brahmer, Julie R. ;

Muzikansky, Alona ;

Bonomi, Philip D. ;

del Prete, Salvatore ;

Wurtz, Anna ;

Farago, Anna F. ;

Dias-Santagata, Dora ;

Mino-Kenudson, Mari ;

Reckamp, Karen L. ;

Yu, Helena A. ;

Wakelee, Heather A. ;

Shepherd, Frances A. ;

Piotrowska, Zofia ;

Sequist, Lecia V. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) :278-+

[7] Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes [J].

Offin, Michael ;

Chan, Joseph M. ;

Tenet, Megan ;

Rizvi, Hira A. ;

Shen, Ronglai ;

Riely, Gregory J. ;

Rekhtman, Natasha ;

Daneshbod, Yahya ;

Quintanal-Villalonga, Alvaro ;

Penson, Alexander ;

Hellmann, Matthew D. ;

Arcila, Maria E. ;

Ladanyi, Marc ;

Pe'er, Dana ;

Kris, Mark G. ;

Rudin, Charles M. ;

Yu, Helena A. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :1784-1793

[8] Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation [J].

Quintanal-Villalonga, Alvaro ;

Taniguchi, Hirokazu ;

Zhan, Yingqian A. ;

Hasan, Maysun M. ;

Chavan, Shweta S. ;

Meng, Fanli ;

Uddin, Fathema ;

Manoj, Parvathy ;

Donoghue, Mark T. A. ;

Won, Helen H. ;

Chan, Joseph M. ;

Ciampricotti, Metamia ;

Chow, Andrew ;

Offin, Michael ;

Chang, Jason C. ;

Ray-Kirton, Jordana ;

Tischfield, Sam E. ;

Egger, Jacklynn, V ;

Bhanot, Umesh K. ;

Linkov, Irina ;

Asher, Marina ;

Sinha, Sonali ;

Silber, Joachim ;

Iacobuzio-Donahue, Christine A. ;

Roehrl, Michael H. ;

Hollmann, Travis J. ;

Yu, Helena A. ;

Qiu, Juan ;

de Stanchina, Elisa ;

Baine, Marina K. ;

Rekhtman, Natasha ;

Poirier, John T. ;

Loomis, Brian ;

Koche, Richard P. ;

Rudin, Charles M. ;

Sen, Triparna .

CANCER DISCOVERY, 2021, 11 (12) :3028-3047

[9] A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms [J].

Rivera-Concepcion, Joel ;

Lo, Ying-Chun ;

Uprety, Dipesh ;

Adjei, Alex A. ;

Ernani, Vinicius ;

Leventakos, Konstantinos .

CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2024, 13

[10] Histologic transformation in lung cancer: when one door shuts, another opens [J].

Sato, Yuki ;

Saito, Go ;

Fujimoto, Daichi .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14

← 1 2 →